Alyeska Investment Group, L.P. Bio Line Rx Ltd. Transaction History
Alyeska Investment Group, L.P.
- $18 Billion
- Q3 2024
A detailed history of Alyeska Investment Group, L.P. transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 866,495 shares of BLRX stock, worth $415,917. This represents 0.0% of its overall portfolio holdings.
Number of Shares
866,495
Previous 1,953,366
55.64%
Holding current value
$415,917
Previous $1.11 Million
58.04%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding BLRX
# of Institutions
37Shares Held
3.3MCall Options Held
46.5KPut Options Held
6.3K-
Cvi Holdings, LLC Wilmington, DE816KShares$391,5274.05% of portfolio
-
Envestnet Asset Management Inc239KShares$114,8090.0% of portfolio
-
Morgan Stanley New York, NY198KShares$94,8170.0% of portfolio
-
Values First Advisors, Inc.198KShares$94,8070.06% of portfolio
-
Atria Investments LLC Charlotte, NC134KShares$64,3070.0% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $29.5M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...